Cellenis® PRFM (Platelet Rich Fibrin Matrix) is a fibrin gel matrix that is derived by
combining Cellenis® PRP with autologous thrombin. Cellenis® Thrombin Rich Serum (TRS) is a major byproduct of Cellenis® PRF.
PRFM produced by PRP activation with TRS, provides a flexible platform that enables control of PRP concentration. Platelet concentration of at least one million/microliter is considered therapeutically effective. The platelet concentration affects the matrix viscosity and different growth factor release patterns. PRP activation with autologous thrombin shows an immediate release of PDGF and TGF that remains stable over time. VEGF demonstrates an increasing trend from 15 minutes up to 24 hours. PRFM platform enables also the control over the matrix diameter.